Business Model Breakdown
How Microbot Medical Inc Makes Money
MBOT
Market Cap
$136M
Annual Revenue
$105,000
Profit Margin
-3496.2%
Employees
20
The Short Version
Microbot Medical Inc. is a pre-profitability medical device company focused on developing and commercializing disposable micro-robotic systems for minimally invasive endovascular surgical procedures. Its flagship product, the FDA-cleared LIBERTY system, aims to provide physicians with enhanced precision and control, potentially improving outcomes for complex procedures. The company primarily intends to generate revenue through the sale of these robotic systems to hospitals and surgical centers, along with recurring revenue from sales of specialized disposable components used in each procedure, operating on a 'razor-and-blade' model.
Where the Revenue Comes From
Sales of LIBERTY Endovascular Robotic Systems (initial revenue reported Q1 2026)
Sales of single-use disposable micro-catheters and related consumables (future recurring revenue)
Who buys: Hospitals, surgical centers, interventional suites, and medical professionals performing endovascular procedures.
Why It Works (Competitive Advantages)
- ✔Proprietary micro-robotic technology and intellectual property for endovascular procedures.
- ✔FDA-cleared LIBERTY system, a significant regulatory hurdle passed, and subsequent Israeli approval.
- ✔Potential for first-mover advantage in this specialized micro-robotic endovascular segment.
Economic Moat: Narrow (Intangible Assets/IP (patents on micro-robotic technology), Switching Costs (for hospitals and physicians who invest in training and workflow integration))
What Our Analysis Says
DVR Score as of June 1, 2026
Microbot Medical remains a high-risk, high-reward proposition with compelling 10x potential in the robotic endovascular surgery market. The significant milestone of reporting first LIBERTY commercial revenue in Q1 2026, coupled with the transition to Full Market Release and recent regulatory approval in Israel, marks substantial progress in validating its strategic vision and technology. These developments partially mitigate previous concerns about an urgent need for revenue, despite the stock's initial negative reaction. While immediate financial health remains precarious due to its pre-profitability status and unquantified cash burn (from the provided data), the company is now actively commercializing its core product. The proprietary technology provides a competitive edge, but scaling operations and securing further funding will be critical to capitalize on the vast market opportunity.